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a b s t r a c t
We characterized three subsets of NK cells in blood, and two subsets in mucosal tissues. SIVmac251 infection
increased total and CD16þ NK cells in the blood. In the rectum, we observed a signiﬁcant increase in total
and NKG2Aþ NK cells during SIV infection. In contrast, the NKp44þ subset signiﬁcantly depleted in acute
infection and continued to decline in frequency during chronic phase. During SIV infection, blood CD16 and
mucosal NKG2Aþ subsets had increased cytotoxic potential. Intriguingly, the NKp44þ NK cell subtype that
likely mediates mucosal homeostasis via the production of cytokines, acquired cytotoxicity. Antiretroviral
therapy signiﬁcantly increased the frequency of mucosal NKG2Aþ NK cells and peripheral CD16þ NK cells.
However, it failed to restore the normal frequency of NKp44þ NK cells in the rectum. Thus, SIVmac251
infection causes changes in the distribution and function of NK cells and antiretroviral therapy during chronic
infection only partially restores NK homeostasis and function.
Published by Elsevier Inc.
Introduction
Understanding of the innate and adaptive immunological
mechanisms that curtail HIV infection and dissemination will
facilitate the development of more effective vaccines or therapies
to combat HIV. The early phase of HIV infection is critical as the
outcomes of the interaction between the virus and the immune
system during this phase is likely to determine whether the virus
is eliminated, locally controlled, or disseminates to the rest of the
body (Naranbhai et al., 2013; Ansari et al., 2011). While it is clear
that there is a rapid activation of innate immune responses after
viral exposure (Chang and Altfeld, 2010; Haase, 2010) details on
innate cell types and their role in the immune responses to HIV
remains unclear.
NK cells are part of the innate immune system, which is the body's
initial defense against viral infections (Reeves et al., 2010a; Moretta
et al., 2002). They kill virus-infected and neoplastic cells, via multiple
mechanisms, including degranulation of cytotoxic granules and activa-
tion of death receptors (Cooper et al., 2001). NK cells also secrete a
wide range of cytokines and chemokines that are pro-inﬂammatory or
anti-inﬂammatory and are involved in regulating the adaptive
immune responses (Farag and Caligiuri, 2006; Cooper et al., 2001).
Increasing evidence supports an important role of NK cell subsets,
in controlling HIV and SIV infection, both directly and indirectly
(Ackerman et al., 2012; Fauci et al., 2005). Recent studies have
demonstrated a signiﬁcant association between slower HIV-I disease
progression and the presence of NK cell killer immunoglobulin-like
receptor gene (KIR3DS1) with its ligand HLA-B alleles (Bw4-80lle)
(Boulet et al., 2008; Martin et al., 2002). Furthermore, Alter et al. (2011)
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showed HIV-I adaptation to NK cell mediated immune pressure.
NK cells in conjunction with antibodies, can also kill target cells by
antibody-dependent cellular cytotoxicity (ADCC) and antibody-
dependent cell-mediated virus inhibition (ADCVI) (Chung et al.,
2008). A recently concluded Phase III HIV vaccine trial (RV144),
demonstrated 31% protection from infection, and an inverse
correlation between the risk of HIV acquisition and ADCC
(Bonsignori et al., 2012). Therefore, a better understanding of the
mechanism of NK cells and HIV interactions may be important for
the development of HIV vaccines.
Our lab and others have shown that SIV infection of Rhesus
macaques is a valuable tool to mimic natural HIV infection in
humans (Pegu et al., 2013; Morgan et al., 2008; Ansari et al., 2011).
The majority of HIV infections are acquired through sexual
transmission, thus HIV enters the body through the vaginal, rectal,
or penile mucosa. In the initial phase, a small number of founder
viruses may infect target cells in the mucosa and expand locally.
Within few days however, the virus disseminates systemically and
a persistent infection is established (Haase, 2005; Hladik and
Hope, 2009; Yu and Vajdy, 2010). Recent reports suggest that the
role of innate immune components, present at the mucosal site
during this early phase of the infection, may determine the disease
outcome (Borrow, 2011; Ansari et al., 2011).
Although, NK cell subsets have been described in human
mucosal tissues, most of the studies on NK cell responses during
HIV infection are limited to human peripheral blood (Sips et al.,
2012; Alter et al., 2005). This is mainly due to practical difﬁculties
in obtaining appropriate samples (vaginal or rectal mucosa) from
humans. Recent transcriptional studies have shown a high degree
of homology between Rhesus macaques and human NK cells
(Hong et al., 2013). Thus, macaques are a powerful and relevant
model to study how SIV/HIV infection changes NK cells frequency
and function.
Accurate identiﬁcation of NK cells subsets in the blood and
tissues of nonhuman primates is complex and requires several
surface markers (Pereira et al., 2008). Rhesus macaque peripheral
blood NK cells are generally deﬁned as CD3CD20CD8ααþ and
NKG2Aþ . NK cells can be further subdivided into three groups
depending on the degree of CD56 and CD16 receptors expression
(Reeves et al., 2010b; Hong et al., 2013; Ansari et al., 2011).
The majority of naïve Rhesus macaques blood NK cells are
CD16þ/CD56 (CD16 subset) and considered to be more cytotoxic,
whereas the smaller CD16/CD56þ (CD56) subset produces more
cytokines. In contrast, the CD16CD56 (DN subset) may have
both properties (Webster and Johnson, 2005; Pereira et al., 2008;
Ansari et al., 2011).
Classiﬁcations of mucosal NK cell subsets are rather compli-
cated. According to the recent classiﬁcation, gut associated NK
cells in human and mouse are grouped in the innate lymphoid cell
group1 (ILC-group 1) (Walker et al., 2013). However, two distinct
NK cell subsets were recently deﬁned in the mucosal tissues of the
Rhesus macaque depending on NKp44 and NKG2A expression
(Reeves et al., 2011). In naïve animal's NKG2Aþ NK cells are more
cytotoxic and NKp44þ NK cells produce cytokines. NKp44þ NK
cells closely resemble the NK22 cells reported in human mucosal
tissues (Cella et al., 2009) and they produce LIF, BAFF, and
cytokines including IL17 and IL22 (Reeves et al., 2011). Thus, the
NKp44þ subset may be important in maintaining gut mucosal
integrity and regulating B-cell function.
Highly active anti-retroviral therapy (HAART) effectively sup-
presses HIV replication, restores CD4þ T-cell counts in blood, and
reduces HIV morbidity. However, little is known about NK cell
frequency and function in blood and tissues during HAART
therapy. Indeed, only few studies addressed the effect of HAART
on mucosal NK cell subsets (Costiniuk and Angel, 2012; Mela et al.,
2007). Peripheral blood NK cells from patients treated with HAART
showed durable activation of NK cells, and also reported a decrease
in the expression of FcR-γ111 receptor and reduced ADCC signaling
(Lichtfuss et al., 2012; Leeansyah et al., 2010). Another study has
shown a signiﬁcant increase of NK cells in colonic lamina propria
after HAART treatment in humans (Mela et al., 2007).
In this study, we characterized the NK cell subsets and their
phenotypic and functional alterations during acute and chronic SIV
infection in peripheral blood and rectal mucosa and also studied the
changes of NK cell subsets after anti-retroviral therapy. During the
acute phase of SIV infection, we observed a rapid increase of cytotoxic
NK cells (CD16 NK cells) in the blood and NKG2Aþ NK cell subsets in
the gut. Mucosal NKp44þ cell subsets rapidly decreased in the acute
phase and further decreased during the chronic phase. Mucosal
NKG2Aþ and NKp44þ NK cells altered their phenotypic and func-
tional characteristics during SIV infection. This may lead to alteration
of the gut homeostasis and subsequent chronic immune activation
and disease progression. HAART treatment signiﬁcantly increased
CD16 NK cells in the blood and NKG2Aþ NK cell subsets in the gut.
However, mucosal NKp44þ NK cell subsets continue to decline, even
after ART treatment in the chronically infected macaques.
Results
Phenotypic and functional characterization of NK cells subsets in the
blood and mucosa of healthy un-infected macaques
Recent studies have deﬁned macaque peripheral blood NK cell
as CD3CD8ααþ NKG2Aþ (Total NK cells) (Xu et al., 2012; Reeves
et al., 2011, 2010b). Three different NK cell subsets are identiﬁed
based on the expression of surface receptors CD56 and CD16
(Fig. 1A). The predominant peripheral blood NK cell subsets are the
CD16þ CD56 (CD16 subset) and the CD56 and CD16 (DN)
cells, while the least frequent subset is the CD56þ CD16 (CD56
subset) (Fig. 1B). We characterized the activation/apoptotic poten-
tial, homing and cytokine production of each subset in the blood.
The DN subset expresses the highest levels of the active form of
caspase 3, suggesting a higher rate of turnover (Fig. 1C). The CD16
subset expresses the highest level of the CCR6, a gut homing
marker (Ito et al., 2011) (Fig. 1D). The CD16 subset produced higher
CD107a and low IFN-γ and TNF-α where as the CD56 subset
produced higher IFN-γ and TNF-α when stimulated with 721.221
cells. This indicates that CD16 subset is potentially more cytotoxic
while cytokine production may be a key feature of the CD56 NK
subset in naïve rhesus macaque peripheral blood (Fig. 1E).
Next, we studied the mucosal NK cell subsets in naïve maca-
ques. Human mucosal NK cell subsets have been reclassiﬁed as an
innate lymphoid cell Group1 (Walker et al., 2013). However, two
different NK cell subpopulations have been recently reported at
the mucosal tissues of rhesus macaques (Reeves et al., 2010b).
Using a comparable gating strategy (Supplemental Fig. 1), we
observed two distinct NK subpopulations; NKG2Aþ NKp44
(NKG2Aþ subset) and NKp44þNKG2A (NKp44þ subset) in the
mucosal tissues (Fig. 2A). The NKG2Aþ cells were the most
frequent in mucosal tissues. Interestingly, the highest NKG2Aþ
frequency was observed in vaginal tissues followed by mesenteric
lymph nodes, bronchoalveolar lavage (BAL), and rectal biopsies
(Fig. 2A and B), whereas NKp44þ NK cells were predominantly
present in the rectal biopsies and mesenteric lymph nodes (Fig. 2A
and C). We did not ﬁnd NKp44þ NK cells in peripheral blood,
auxiliary, inguinal, or obturator lymph nodes in naive Rhesus
macaques (Fig. 2A). Most of the gut associated NKG2Aþ NK cells
expressed the classical NK cell marker CD56, and more than 50% of
cells expressed CD16. However, NKp44þ cells expressed low
amounts of CD56 and no CD16 in naïve animals (Fig. 2D and E).
Although frequencies of NKp44þ NK cells were lower than
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NKG2Aþ cells, they expressed higher levels of CCR6 than NKG2Aþ
cells (Fig. 2F). We did not observe a signiﬁcant difference in
proliferation or CCR5 expression between these subsets (data not
shown). Since NK cells exhibit either cytotoxic, cytokine producing
capabilities, or both, we stimulated mucosal NK cells with mito-
gens and measured intracellular cytokine production and expres-
sion of the degranulation marker CD107a. CD107a or LAMP-1 has
been described as a functional marker for NK cells. CD107a on NK
cells correlate with target cell lysis. Therefore, expression of
CD107a can be use to estimate cytotoxic capability of NK cells
(Alter et al., 2004). Following PMA and ionomycin stimulation,
NKG2Aþ cells showed higher CD107a expression and signiﬁcantly
elevated IFN-γ production indicating a potential cytotoxic role.
NKp44þ cells produced higher amounts of IL17 and TNFα upon
mitogenic stimulation, however they produce very little IFN-γ and
no expression of CD107a (Fig. 2G). These data suggest that
NKp44þ cells have a regulatory role in gut mucosal tissues rather
than a cytotoxic role.
Blood and gut NK cell subsets in Rhesus macaques during acute and
chronic SIV infection
We studied the changes in the frequency of NK cell subsets
in the blood and rectal mucosa during the acute and chronic
phases of SIV infection. During the acute phase, total NK cells
(CD3CD20CD8ααþNKG2Aþ) in the blood were increased com-
pared to naïve animals and continued to increase during the
chronic phase (Fig. 3A). The CD16þ NK cell subset was increased
signiﬁcantly in acute infection and then began to decline during
the chronic phase but remained higher than the pre-infection level
(Fig. 3A). The CD56 subset showed a slight decrease, however it
was not signiﬁcant. Interestingly, the DN subset was signiﬁcantly
reduced during the acute phase, but gradually increased to pre
infection level in the chronic phase (Fig. 3A). Of note, no correla-
tion was observed between CD4 T cell count, viral load or
frequency of CD4 Ki67þ in the blood and CD16 NK cell subset
(Supplemental Fig. 2) or any other peripheral NK cell subset (Data
not shown).
We further examined the mucosal NK cells responses during
acute and chronic SIV infection. Similar to the total peripheral blood
NK cells, total NK cells (CD3CD20) in the gut also increased
signiﬁcantly post SIV infection and peeked during the acute phase.
Further analysis of subsets showed that the NKG2Aþ subset
increased in acute SIV infection yet returned to the baseline levels
in the chronic phase. Interestingly, NKp44þ cell subsets were
severely depleted during acute infection and continued to decline
in the chronic phase (Fig. 3B). Loss of NKp44þ , cells that produce IL17
and potentially IL22, may lead to a loss of intestinal integrity causing
microbial translocation and an increase in immune activation.
Chemokine receptor 6 (CCR6) expression on NK cells during SIV
infection
CCR6 is the receptor for CCL20 ligand, which is primarily
expressed in the gut. The CCR6/CCL20 combination plays an
important role in gut immunity (Ito et al., 2011). CCR6 expression
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Fig. 1. Phenotypical and functional characterization of NK cell subsets in peripheral blood of naïve Rhesus macaques. (A). Representative ﬂow cytometric gating
strategy to identify NK cell subsets in peripheral blood of naïve Rhesus macaques. Macaque's blood NK cells were gated as CD3-CD20-CD8ααþ NKG2Aþ cells. They were
further delineated by expression of CD16 and CD56 receptors. (B). Relative distribution of different NK cell subsets CD16 (CD56CD16þ), CD56 (CD56þCD16) and DN
(CD56CD16) in the peripheral blood. (C) Expression of Caspase-3 or (D) chemokine receptor CCR6 was measured on blood NK cell subsets. (E) Peripheral blood
mononuclear cells were stimulated with 721.122 cells (E:T ratio at 5:1) for 12 h and measured CD107a expression, IFN-γ and TNF-α production on CD16, CD56 and DN NK cell
subsets in naive macaques. The data represents seven naïve animals. Only signiﬁcant P values are shown. Mann–Whitney test used to compare two groups and; 1way ANOVA
used to compare multiple groups (nPo .05; nnPo .01; nnnPo .001). (ns: non signiﬁcant).
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on NK cells may indicate a possible gut homing signature. Thus,
we next examined the expression of CCR6 on NK subsets during
the SIV infection in the peripheral blood and the gut. We observed
increased expression of CCR6 on the CD56 subset of NK cells in the
blood during the acute phase and a signiﬁcant elevation during the
chronic phase as well (Fig. 3C). Similarly, we observed increased
CCR6 expressions of DN NK cells in the blood. The CD16 subset
showed a slight increase of CCR6 on their surface during acute
infection but was reduced signiﬁcantly in the chronic phase. In the
rectal mucosa, the NKp44þ subset did not show alteration of CCR6
expression on their surface; however the NKG2Aþ subset had
signiﬁcantly increased CCR6 expression during the chronic phase
(Fig. 3D).
Functional alteration of blood and gut NK cell subsets during acute
and chronic SIV infection
NK cells have both effector and regulatory functions. A recent
study on human gut mucosal NK cells showed two different NK cell
populations present in the intraepithelial layer (IEL) and lamina
propria (LP). Spontaneous controllers showed a stable IEL NK cell
subset, suggesting a potential role of gut NK cells in virus control
(Sips et al., 2012). Therefore, the alteration of NK cell functions may
affect viral control and dissemination of the infection. We studied the
functional proﬁles of mucosal NK cell subsets during acute and
chronic infections. We stimulated total rectal mucosal lymphocytes
with PMA and ionomycin for 12 h and analyzed their functional
changes during acute and chronic infections.
Interestingly, NKp44þ NK cell subsets demonstrated higher levels
of CD107a production in the acute phase of the infection, which
declined in the chronic phase but remained signiﬁcantly higher than
naïve animals (Fig. 4A). Expression of CD107a by NKp44þ cells was
surprising and suggests that the NKp44þ NK cell subset acquired
cytotoxic capabilities when exposed to SIV (Fig. 4A). In addition, the
NKp44þ subset demonstrated signiﬁcantly increased production of
Th1 cytokine IFN-γ during all stages of SIV infection (Fig. 4B).
Conversely, TNF-α and IL17 production was signiﬁcantly decreased
in the NKp44þ subset, which could indicate a reduction in their
ability to regulate mucosal homeostasis (Fig. 4C and D). NKG2Aþ NK
cells, the dominant NK cell subset in the gut, also had increased
expression of CD107a during the chronic phase (Fig. 4A). Production
of IFN-γ from NKG2Aþ cells were signiﬁcantly increased during the
acute phase but reduced during progression to the chronic phase
(Fig. 4C and D). TNF-α production was signiﬁcantly reduced in
NKG2Aþ cells during acute SIV infection but increased during
progression to the chronic phase (Fig. 4C). NKG2Aþ cells produced
very low amounts of IL17 in naïve animals and a further signiﬁcant
decrease was observed in SIV infection (Fig. 4D).
Naïve and infected blood NK cell subsets were analyzed for
functional changes after stimulation with 721.221 cells, as described
in “Material and methods” section. We measured expression of the
degranulation marker CD107a and production of IFN-γ, and TNF-α
by different NK cell subsets. During the acute phase, CD107a
expression was increased in all subsets. Interestingly, CD107a
expression on the DN subset was signiﬁcantly reduced in the
chronic phase (Fig. 4E). IFN-γ production was elevated in CD16
Un-infected macaques (Mucosa)
Fig. 2. Tissue distribution and functional characteristics of rectal mucosal tissue NK cell subsets in naïve Rhesus macaques. (A) Flow cytometry plots comparing the
tissue distribution of NKG2Aþ and NKp44þ NK cell subsets in a representative naïve Rhesus macaque using a gating strategy shown in Supplemental Fig. 1. Frequency of
(B) NKG2Aþ NK subset and (C) NKp44þ subset in rectal mucosa, vaginal tissues and mesenteric lymph nodes (MLN). (D) Flow cytometry plots comparing CD56 and CD16
receptor expression on NKp44þ and NKG2Aþ NK cell subsets in rectal mucosal tissues of uninfected macaques. (E) CD16 receptor expression on NKp44þ and NKG2Aþ in the
gut in rectal mucosal tissues of seven uninfected macaques. (F) Differential distribution of chemokine receptor 6 (CCR6) in rectal mucosal NK cell subsets in naïve macaques.
(G) Intracellular cytokines production of TNFα, IFNγ, and IL17 and CD107a expression measured in the rectal mucosal NK cell subsets of naïve macaques after 12hrs of phorbol
12-myristate 13-acetate/ionomycin stimulation. The data represents three to seven naïve animals. Only signiﬁcant P values are shown. Mann–Whitney test used to compare
two groups and; Kruskal–Wallis tests used to compare multiple groups (nPo .05; nnPo .01; nnnPo .001).
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subsets during the chronic phase (Fig. 4F) whereas; TNF-α produc-
tion was transiently elevated during the acute phase in DN and
CD56 subsets (Fig. 4G).
Incomplete restoration of NK cell subsets in blood and rectal mucosa
of infected macaques treated with ART
ART therapy can lead to partial restoration of the peripheral
and mucosal immune system. However, the effect of ART on the
innate immune system, particularly NK cell subsets, has not been
extensively studied. Therefore, in this study, seven chronically
infected Rhesus macaques were treated with antiretroviral treat-
ment for 11 weeks (Fig. 5A). ART signiﬁcantly reduced plasma viral
load (Fig. 5B), as well as SIV DNA in rectal biopsies (Fig. 5C). The
effect of ART on NK cells in blood and rectal mucosa were studied
by multi-parametric ﬂow cytometry. The CD16 NK cell subset in
the peripheral blood signiﬁcantly increased after ART treatment.
However, DN population (Fig. 5D) demonstrated a signiﬁcantly
lower frequency when compared to naive animals. In rectal
mucosa, the NKG2Aþ NK subset was signiﬁcantly elevated after
ART treatment (Fig. 5E). However, the NKp44þ NK cell subset
remained depleted despite ART treatment (Fig. 5E). No ART
mediated functional changes were observed in any blood NK cell
subsets stimulated with 721.221 cells (Fig. 5F–H).
Discussion
NK cells are a heterogeneous population that plays an impor-
tant role in many viral infections and are involved in controlling
SIV and HIV infection (Ansari et al., 2011; Naranbhai et al., 2013).
They are part of the innate defense systems in the body and
inﬂuence the development of adaptive immune responses.
We assessed peripheral blood NK cells in macaques based on a
previously reported gating strategy (Reeves et al., 2010b). We found
that the CD16 subset is the most abundant NK cell population in the
peripheral blood of naïve animals. This is consistent with ﬁndings in
the peripheral blood of humans (Reeves et al., 2010b). Our results
Fig. 3. Dynamics of NK cell subsets during acute and chronic phases of SIV infection in the peripheral blood and rectal mucosal tissues of Rhesus macaques. Dot plots
represent the frequency of different NK cell subpopulations in the (A) peripheral blood and (B) rectal mucosal tissues of Rhesus macaques during acute and chronic SIV
infections. Previously vaccinated animals are indicated with open symbols. There were no differences in viral loads or CD4 counts between vaccinated and unvaccinated
animals (Supplemental Table 1). (C) Bar graphs represent the average and standard deviation for the levels of CCR6 expression on subsets of NK cell in peripheral blood
and (D) rectal mucosa during acute and chronic SIV infection. Kruskal–Wallis tests were used for comparisons of each group. Data represents the seven animals per group.
Only signiﬁcant P values are shown (nPo .05; nnPo .01; nnnPo .001).
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also indicate a cytotoxic role for CD16 cells and a cytokine producing
role for CD56 and DN subsets that express the highest levels of IFNγ
and TNFα after in vitro stimulation.
The chemokine receptor CCR6 expressed by lymphocytes,
including NK cells, binds to the chemokine ligand CCL20 and is
an important receptor involved in regulating mucosal immunity
Fig. 4. Alteration of functional capability during acute and chronic SIV infection in rectal mucosal NK cell subsets. Bar graphs represent the average and standard
deviation for (A) expression of CD107a (B) and levels of IFN-γ, (C) TNF-α and (D) IL17 secretion following a 12 h stimulation with phorbol 12-myristate-13-acetate (PMA)/
ionomycin for the subsets of NK cells in rectal mucosa of naïve, SIV acute and SIV chronically infected Rhesus macaques. Peripheral blood mononuclear cells were stimulated
with 721.122 cells at E:T ratio of 5:1 for 12 h and measured (E) CD107a, (F) IFN-γ and (G) TNF-α production on Total, CD16, CD56 and DN NK cells subsets in naïve, acute and
chronically SIV infected animals. Data represents the seven animals per group. Kruskal–Wallis tests were used for comparisons of each group. Only signiﬁcant P values are
shown (nPo .05; nnPo .01; nnnPo .001).
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Fig. 5. The effects of ART treatment on peripheral blood and gut NK cell subsets in SIV chronically infected Rhesus macaques. (A) Diagram representing ART treatment
schedule. Chronically infected seven Rhesus macaques were treated with ART as described in “Material and methods” section. Samples were collected pre-ART, and 11 weeks
post treatment from peripheral blood and gut tissues and the NK cell responses were evaluated. (B) Plasma viral load (SIV RNA) and (C) SIV viral load (SIV DNA) in rectal
mucosa. The dot plots represent the changes of (D) blood NK cell subsets and (E) rectal mucosal NK cell subsets during pre- and post-ART treatment. Prior vaccinated animals
are indicated in open squares or open triangles. As indicated in Supplemental Table 1, there were no differences in viral loads or CD4 counts between vaccinated and
unvaccinated animals. Bar graphs represent the average and standard deviation for (F) expression of CD107a (G) and levels of IFN-γ and (H) TNF-α production by peripheral
blood NK cell subsets following a 12 h stimulation with 721.122 cells at a E:T ratio of 5:1. Kruskal–Wallis tests were used for comparisons of each group. Only signiﬁcant P
values are shown (nPo .05; nnPo .01; nnnPo .001).
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(Alter at al, 2004). Here, we observed higher CCR6 expression on
CD16 NK cells compared to other NK subsets in naïve animals.
Reeves et al. (2010b) showed that the CD16 NK cell subset did not
express lymph node homing markers such as CCR7 and CD62L
(Reeves et al., 2010b). Therefore, we can speculate that the CD16
NK subset may be capable of migration to mucosal sites.
Mucosal NK cell subsets are more complicated in classiﬁcation.
A recent study has shown two different NK cell subsets present in
mucosal tissues which include NKG2Aþ and NKp44þ NK cell
subsets (Reeves et al., 2011). The NKG2Aþ NK subset is similar to
blood NK cells and exhibits cytotoxic properties and is the
dominant NK cells in the gut and many other mucosal tissues.
Interestingly, we observed that the frequency of NKG2Aþ NK cells
was higher in vaginal tissues and in the lung than any other tissue.
NKp44þ NK cells are cytokine producing cells and may represent
the human NK22 counterpart. Other researches also suggest that
this subset is a part of innate lymphoid cell group (Xu et al., 2012).
In naïve animals, NKp44þ NK cells produce IL17 and TNFα and are
present mainly in mucosal tissues, such as rectal mucosa, gut
tissues, or mucosal associated lymphoid tissues like mesenteric
lymph nodes, indicating that this subset may be associated with
mucosal immunity. Interestingly, CCR6 expression is also higher in
the NKp44þ NK subset suggesting that this subset may circulate
between inductive and effector sites within mucosal sites.
The initial interactions of HIV/SIV with the immune system
during the acute phase is critical to the outcome of the infection
(Borrow, 2011). This phase determines whether the virus will be
eliminated, or becomes established and the individual progresses
to a chronic infection. We evaluated both peripheral blood and
mucosal NK cell responses during the acute and chronic phases
of the infection. Consistent with NK cell responses during acute
HIV (Alter et al., 2005) and SIV infections, we also showed that
CD16þ , the cytotoxic NK cell subset in the blood, increased
signiﬁcantly during the acute phase and declined during the
chronic phase of infection. CD16þ cells also showed signiﬁcantly
higher IFNγ production during the chronic phase. This early
expansion of the CD16þ NK cell subset may be important for
initial viral control. We also observed that the frequency of
multifunctional DN NK cells in the blood is reduced during the
acute phase with a slight increase during the chronic phase of
infection. DN NK cells expressed higher levels of lymph node-
homing marker CCR7 and CD62L (Reeves et al., 2011). Thus, initial
reduction of DN cells in the blood may be due to trafﬁcking to the
lymph nodes during acute infection. The CD56 subset, which
expressed CCR5, CCR6, CXCR3, and CXCR4 (Reeves et al., 2010a, b)
decreased during chronic phase but did not show signiﬁcant
changes during both acute and chronic infection. However, TNFα
production of this subset signiﬁcantly reduced during the chronic
phase. Interestingly, CCR6 expression in CD56 subset was signiﬁ-
cantly increased during the chronic phase of infection. This may
suggest a possible recruitment of this NK cell subset to the mucosal
tissues as infection progresses.
The frequency of cytotoxic mucosal NK cell subset (NKG2Aþ)
was transiently increased during acute infection in the rectal
mucosa, where the virus primarily replicates. The cells also
signiﬁcantly increased production of IFNγ during the acute phase
of infection. This may improve the anti-viral status in the gut
before the induction of adaptive immune cells. With progression
to the chronic phase of infection, we observed a loss of frequency
and a signiﬁcant reduction of IFNγ production, which indicates the
suppression of NK cell function during the chronic stages of the
infection. However, the cytotoxic capability remained signiﬁcantly
increased. In addition, the NKp44þ NK cell subset was signiﬁ-
cantly reduced during the acute and chronic phase of infection.
This subset also exhibited a signiﬁcant reduction of IL17 and TNFα
producing cells during disease progression. IL17, together with
TNFα, has been shown to be an important cytokine in the host
defense (Hartupee et al., 2007; Xu et al., 2012). Previous studies
have shown that the IL17 producing cells were important for
mucosal epithelial integrity during SIV and HIV infection
(Brenchley et al., 2008; Hartigan-O’Connor et al., 2011; Reeves
et al., 2011). Therefore, the loss of IL17 producing NKp44þ cells
during infection in the gut may have a signiﬁcant impact on gut
homeostasis during SIV infection in macaques. Furthermore,
NKp44þ cells signiﬁcantly changed their functional capacity. The
reduced IL17 production and TNFα production occurred in con-
junction with a signiﬁcant increase in the production of CD107a
and IFNγ production during infection. Taken together, our study
has shown that rapid changes occur both in the frequency and in
the function of different NK cell subsets during the course of SIV
infection.
HAART therapy restores CD4þ T-cell counts in blood and has
reduced the incidence of AIDS in HIV-infected individuals. However,
little is known about NK cell responses during HAART therapy. There
are only a few reports about the mucosal NK cell subset during
HAART therapy (Costiniuk and Angel, 2012; Mela et al., 2007). Recent
reports from HAART treated patient's peripheral blood NK cells
showed continued activation of NK cells and decreased expression
of FcR γ and reduced ADCC signaling. In this study, we showed that
with ART treatment, the CD16 NK cell subset signiﬁcantly increased
in the blood. However, we did not observe restoration of functional
capability of blood NK cells after ART. Interestingly, the frequency of
the cytotoxic NKG2Aþ NK cell subset in the rectal mucosa was also
signiﬁcantly elevated. Nevertheless, NKp44þ NK cell subsets con-
tinuously declined during ART. Thus, we observed a continued
alteration of NK cell subsets in chronically infected macaques treated
with ART. Further studies are needed to gain better understanding of
the effect of antiretroviral therapy on HIV/SIV infections.
We have studied NK cell subsets in the peripheral blood and
mucosal tissues during acute and chronic SIV infection and while we
observed no signiﬁcant associations with virus loads, we do observe
signiﬁcant alterations in NK cells during infection. During the chronic
infection, NK cell subsets in both peripheral blood and mucosal
tissues increased their cytotoxicity. Mucosal tissues, in particular, lost
their cytokine producing NK cell subsets. Interestingly, the expression
of chemokine receptor 6 (CCR6) and their trafﬁcking patterns are
changed during the infection. Furthermore, ART treatment in animals
with chronic SIV infection demonstrated an up regulation of cyto-
toxic NK cell subsets in blood and rectal mucosa but ART failed to
restore cytokine producing NKp44þ cells.
Materials and methods
Animals and antiretroviral therapy
We studied a total of 32 Indian Rhesus macaques. Twelve animals
were vaccinated with ALVAC-SIV and/or HPV-SIV and gp120 and
20 animals were unvaccinated. All animals were challenged with
repeated low doses of SIVmac251 either intra-rectally or intra-
vaginally. Seven of the 32 animals were followed longitudinally
during the acute and chronic phases. At 6 months post infection,
these seven animals were treated daily with Raltegravir (100 mg/
day/BID), Zerit (Stavudine) (1.2 mg/kg/BID) orally, PMPA (20 mg/kg/
day), and Emtricitabine (FTC) (50 mg/kg/day) subcutaneously. The
prior treatment of these macaques is summarized in Supplemental
Table 1. Naïve samples were collected prior to vaccination and SIV
infection. Post infection samples were obtained 2 weeks post
infection (acute) and 21–41 weeks post infection (chronic). Vaccina-
tion did not reduce SIV viral burden or CD4 loss in the acute or
chronic phase. All of the Rhesus macaques were housed and handled
in accordance with the standards of the Association for the
N.P.M. Liyanage et al. / Virology 450-451 (2014) 359–368366
Assessment and Accreditation of Laboratory Animal Care International,
and the study was reviewed and approved by the Animal Care and Use
Committee at Advanced BioScience Laboratories (Rockville, MD).
Cell culture and ﬂow cytometry
Mononuclear cells from blood and tissues were isolated as
described previously (Vargas-Inc et al., 2011; Reeves et al., 2011).
For the phenotypic characterization, 2106 cells were used, and
ﬂow cytometry staining was carried out for cell surface and
intracellular molecules using standard protocols. NK cell functions
were analyzed using 3106 cells after stimulation with phorbol
myristate acetate (50 ng/mL) and ionomycin (1 μg/mL) or 721.221
cells a MHC-devoid human cell line that are MICA/MICB-negative,
at an effector-target ratio of 5:1. Anti-CD107a (eBioH4A3) was
added directly to each of the tubes at a concentration of 20 μL/mL,
and Golgi Plug™ (Brefeldin A) and Golgi Stop™ (Monensin) were
added at ﬁnal concentrations of 6 μg/mL. All samples were then
cultured for 12 h at 37 1C in 5% CO2. Unstimulated (medium alone)
samples were used as the negative controls. After incubation, cells
were washed and stained for the surface and then ﬁxed and
permeabilized with a Cytoﬁx/Cytoperm Kit™ (BD Biosciences),
and stained for the speciﬁc intracellular molecules. The following
anti-human ﬂuorochrome-conjugated mAbs known to cross-react
with rhesus macaques were used for the staining: V450 anti-IFN-γ
(B27), PE-Cy7 anti-CD56 (NCAM 16.2), Alexa Fluor 700 anti-CD3
(SP34-2), Allophycocyanin-Cy7 anti CD3 (SP34-2), PerCP Cy5.5
anti-CCR6, V450 anti-Caspase 3 (C92-605), Alexa Fluor 700 anti-
Ki67 (B56) (all from BD Biosciences, San Jose, CA); PE-Cy5 anti-
CD107a (eBioH4A3), Alexa 488 anti-IL17 (eBio64DEC17), eFluor
605NC anti-CD20 (2H7), and eFluor 605NC anti-CD8a (RPA-T8) (all
from eBioscience, San Diego, CA); PE anti-NKG2A (Z199), ECD anti-
CD16 (3G8), PE-Cy5 anti-NKp46 (BAB281)(Beckman Coulter, Full-
erton, CA), Fluorescein anti CCR5 (CTC5) (R and D) and allophyco-
cyanin anti-NKp44 (P44-8) and PerCP/Cy5.5 anti-TNF-a (Mab11)
(BioLegend, San Diego, CA). The yellow and aqua LIVE/DEAD
viability dyes (Invitrogen) were used to exclude dead cells. At
least 500,000 singlet events (PBMCs) or 50,000 CD3 singlet
events (mucosal mononuclear cells) were acquired on a LSR II
(BD Biosciences) and analyzed using FlowJo Software (TreeStar).
SIV RNA and DNA measurements
A real-time nucleic acid sequence-based ampliﬁcation assay was
used to measure SIV viral RNA in plasma (Romano et al., 1997).
Plasma was clariﬁed by centrifugation at 2300g for 3 min. Nucleic
acid was isolated as described previously and then analyzed by real-
time nucleic acid sequence-based ampliﬁcation as described pre-
viously. The copy number was expressed per 100 μL of plasma.
The real-time nucleic acid sequence-based ampliﬁcation assay had a
lower limit of sensitivity of 50 copies of RNA (Romano et al., 1997).
Statistical analysis
All statistical and graphical analyses were done using Prism
Version 5.0 software (GraphPad Software). Nonparametric Wilcoxon
matched pairs and Mann–Whitney tests were used where indi-
cated, and Po0.05 was assumed to be signiﬁcant.
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